Fernando Rizzello

Medicine & Life Sciences

1. Crohn Disease 100%
2. Adenocarcinoma 74%
3. Microsatellite Instability 70%
4. Inflammatory Bowel Diseases 67%
5. Keratin-7 66%
6. Ulcerative Colitis 63%
7. Tumor-Infiltrating Lymphocytes 60%
8. DNA Mismatch Repair 56%
9. Carcinoma 47%
10. Turcot syndrome 42%
11. Multicenter Studies 41%
12. Neoplasms 39%
13. vedolizumab 38%
14. golimumab 36%
15. Celiac Disease 33%
16. Surgical Oncology 32%
17. Adalimumab 30%
18. Safety 29%
19. Adjuvant Chemotherapy 28%
20. Italy 24%
21. Colitis 24%
22. Mucous Membrane 21%
23. Intestinal Neoplasms 21%
24. Prospective Studies 20%
25. Anemia 20%
26. Survival 19%
27. Observational Studies 18%
28. Retrospective Studies 17%
29. Ligands 16%
30. Elderly 16%
31. Pathology 15%
32. Apoptosis 14%
33. Therapeutics 11%
34. Colectomy 11%
35. Steroids 11%
36. B7-H1 Antigen 10%
37. Confidence Intervals 10%
38. Colorectal Neoplasms 10%
39. Margins of Excision 10%
40. Phenotype 9%
41. Avitaminosis 9%
42. Practice Guidelines 8%
43. Immunohistochemistry 8%
44. Iron 7%
45. Lymph Nodes 6%
46. Odds Ratio 6%
47. Survival Analysis 6%
48. Hyperplasia 6%
49. Microsatellite Repeats 5%
50. Duration of Therapy 5%